ZS PHARMA , INC. EMPLOYMENT AGREEMENT . This Employment Agreement (this “Agreement”) is entered into between ZS Pharma , Inc.
a Delaware corporation (“ ZS Pharma ”), and Mark Asbury (“Employee”). In consideration of the premises and the following mutual terms and conditions, ZS Pharma and Employee agree as follows: 1. Employment At Will.
9/10/2018 · Sodium zirconium cyclosilicate ( ZS -9) is a selective oral sorbent that traps potassium ions throughout the gastrointestinal tract. It is being developed by ZS Pharma and AstraZeneca for the treatment of hyperkalemia (elevated serum potassium levels). The product was originated at ZS Pharma , a wholly owned subsidiary of AstraZeneca.
9/11/2015 · San Mateo, California-based ZS Pharma ‘s lead experimental drug, ZS -9, is aimed at treating hyperalkemia, a build up of potassium in the body that could lead to heart failure. Analysts at Jefferies said ZS -9 had some overlap with the cardiology component of Actelion’s PAH business, adding that an all-cash deal might be possible.
ZS PHARMA , INC. (Coppell, TX, US) … In another embodiment, an alkoxysilane may be grafted and would require the use of a corresponding alcohol to perform the reaction. Identifying free silanol groups on the surface can done through, for example by, Infrared spectroscopy. In another embodiment, if the material to graft lacks of the active …
5/14/2019 · Model c: model b with the addition of co?morbidities (smoking status, alcohol consumption, diabetes mellitus, eGFR ZS Pharma . M.D. and R.K. are employees of Corvidia Therapeutics. All other authors have …
Search and read the full text of patents from around the world with Google Patents, and find prior art in our index of non-patent literature.
“According to the research study, the global Alcohol Packaging Market was estimated at USD 64 Billion in 2019 and is expected to reach USD 91.3 Billion by 2026. The global Alcohol Packaging Market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2019 to 2026”.
12/29/2020 · Sodium zirconium cyclosilicate (SZC formerly ZS -9) is an oral potassium binder for the treatment of hyperkalemia in adults. SZC acts in the gastrointestinal tract and additionally binds hydrogen ions in acidic environments like the stomach, potentially transiently increasing gastric pH and leading to drug interactions with pH-sensitive drugs.
InstuonalGrantsandContract :%NIH,%HRSA,%Amgen,%AMAG% Pharma ,% Akebia,%AstraZeneca,%DaVita,%Fresenius,%Hospira,%Merck,%NxStage, Novar:s,%Peer%Data%Coordina:ng%Center,%Onyx,% ZS % Pharma ,%Keryx,, 3/20/2019 · It is being developed by ZS Pharma and AstraZeneca for the treatment of hyperkalemia. Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD).
